Tower Research Capital LLC TRC Grows Stock Position in Bioventus Inc. (NYSE:BVS)

Tower Research Capital LLC TRC boosted its stake in shares of Bioventus Inc. (NYSE:BVS) by 106.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,469 shares of the company’s stock after acquiring an additional 1,786 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Bioventus were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Plato Investment Management Ltd bought a new stake in Bioventus in the fourth quarter valued at approximately $38,000. KLP Kapitalforvaltning AS purchased a new stake in Bioventus during the 4th quarter valued at $75,000. Quantbot Technologies LP purchased a new stake in Bioventus during the 4th quarter valued at $103,000. Arizona State Retirement System bought a new stake in Bioventus in the 4th quarter worth $109,000. Finally, HighTower Advisors LLC increased its position in shares of Bioventus by 11.3% in the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after acquiring an additional 1,380 shares during the period. 62.94% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the sale, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. This represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This trade represents a 3.57% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,208 shares of company stock valued at $226,138. Corporate insiders own 32.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Craig Hallum set a $15.00 target price on shares of Bioventus and gave the stock a “buy” rating in a report on Wednesday, May 7th. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Down 2.4%

Shares of Bioventus stock opened at $6.38 on Thursday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12-month low of $5.28 and a 12-month high of $14.38. The company has a market cap of $522.80 million, a P/E ratio of -10.46 and a beta of 0.95. The company’s fifty day simple moving average is $8.22 and its two-hundred day simple moving average is $9.96.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.